Next Article in Journal
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications
Next Article in Special Issue
Unveiling Hidden Dynamics of Hippo Signalling: A Systems Analysis
Previous Article in Journal
Effect of Genetic Diversity in Swine Leukocyte Antigen-DRA Gene on Piglet Diarrhea
Previous Article in Special Issue
The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair

Willing to Be Involved in Cancer

Medical and Biological Sciences Building, School of Biology, University of St Andrews, St Andrews KY16 9TF, UK
Medical and Biological Sciences Building, School of Medicine, University of St Andrews, St Andrews KY16 9TF, UK
Authors to whom correspondence should be addressed.
Present address: Boston University School of Medicine, Silvio Conte Building, Department of Biochemistry, Boston, MA 02118, USA
Academic Editor: Selvarangan Ponnazhagan
Received: 26 April 2016 / Revised: 4 July 2016 / Accepted: 11 July 2016 / Published: 18 July 2016
(This article belongs to the Special Issue Hippo Signaling Pathway)
Genome sequencing is now a common procedure, but prior to this, screening experiments using protein baits was one of the routinely used methods that, occasionally, allowed the identification of new gene products. One such experiment uncovered the gene product called willin/human Expanded/FRMD6. Initial characterization studies found that willin bound phospholipids and was strongly co-localised with actin. However, subsequently, willin was found to be the closest human sequence homologue of the Drosophila protein Expanded (Ex), sharing 60% homology with the Ex FERM domain. This in turn suggested, and then was proven that willin could activate the Hippo signalling pathway. This review describes the increasing body of knowledge about the actions of willin in a number of cellular functions related to cancer. However, like many gene products involved in aspects of cell signalling, a convincing direct role for willin in cancer remains tantalisingly elusive, at present. View Full-Text
Keywords: willin; FRMD6; FERM proteins; cancer willin; FRMD6; FERM proteins; cancer
Show Figures

Figure 1

MDPI and ACS Style

Gunn-Moore, F.J.; Tilston-Lünel, A.M.; Reynolds, P.A. Willing to Be Involved in Cancer. Genes 2016, 7, 37.

AMA Style

Gunn-Moore FJ, Tilston-Lünel AM, Reynolds PA. Willing to Be Involved in Cancer. Genes. 2016; 7(7):37.

Chicago/Turabian Style

Gunn-Moore, Frank J., Andrew M. Tilston-Lünel, and Paul A. Reynolds. 2016. "Willing to Be Involved in Cancer" Genes 7, no. 7: 37.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop